查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561616

2024-2032 年按产品、适应症、配销通路和地区分類的速效胰岛素市场报告

Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球IMARC Group胰岛素市场规模达77亿美元。患者的严重程度和死亡风险不断增加、大众对个人化医疗的日益关注以及研发（R＆D）活动投资的增加是推动市场的一些主要因素。

速效胰岛素是一种用于治疗糖尿病的胰岛素，特别是用于控制餐后血糖高峰。它旨在模仿人体进食后的自然胰岛素反应，注射后 15 分钟内起效。这种迅速的作用有助于有效控制血糖水平，因为它可以调节人体的葡萄糖代谢。速效胰岛素在给药后一到两个小时左右发挥作用高峰，使其能够在这段关键时期有效降低高血糖水平。它允许糖尿病患者根据膳食消耗来安排注射时间，从而提供更个人化的治疗方法。它可以增强糖尿病管理，为患者提供更好的生活质量，并降低与血糖水平失控相关的併发症风险。

速效胰岛素是一种用于治疗糖尿病的胰岛素，特别是用于控制餐后血糖高峰。它旨在模仿人体进食后的自然胰岛素反应，注射后 15 分钟内起效。这种迅速的作用有助于有效控制血糖水平，因为它可以调节人体的葡萄糖代谢。速效胰岛素在给药后一到两个小时左右发挥作用高峰，使其能够在这段关键时期有效降低高血糖水平。它允许糖尿病患者根据膳食消耗来安排注射时间，从而提供更个人化的治疗方法。它可以增强糖尿病管理，为患者提供更好的生活质量，并降低与血糖水平失控相关的併发症风险。

速效胰岛素市场趋势/驱动因素：

大众中糖尿病盛行率不断上升

全世界糖尿病的发生率正以惊人的速度上升。久坐的生活方式、不健康的饮食习惯和肥胖是导致糖尿病发生率上升的一些关键因素。随着越来越多的人被诊断出患有糖尿病，对有效且速效胰岛素的需求持续成长。速效胰岛素在控制餐后血糖高峰方面发挥着至关重要的作用，为患者提供更快、更有效的控制血糖水平的方法。医疗保健提供者越来越多地开出速效胰岛素来满足餐后即时的胰岛素需求，从而降低高血糖和相关併发症的风险。随着糖尿病人口的增加，製药公司正在加大研发投入，以改善速效胰岛素配方，提高其功效并为患者提供便利。

持续的技术进步

医疗技术的创新彻底改变了胰岛素输送系统，使其更加用户友好和准确。胰岛素笔、胰岛素帮浦和连续血糖监测 (CGM) 设备在糖尿病患者中越来越受欢迎，有助于更轻鬆地管理和精确剂量的胰岛素。速效胰岛素製剂旨在与这些现代输送系统完美配合，进一步满足他们的需求。胰岛素笔提供谨慎且方便的胰岛素输送，而胰岛素帮浦则根据个人需求提供连续且个人化的胰岛素输注。这些技术创新改善了血糖控制，降低了低血糖发作的风险，并提高了患者的整体生活品质。因此，速效胰岛素与这些先进设备的兼容性已成为市场成长的重要动力。

提高意识和医疗基础设施

人们对糖尿病及其管理的认识不断提高，加上医疗基础设施的扩大，大大增加了对速效胰岛素的需求。糖尿病意识活动、教育倡议和筛检计画促进了患者的早期诊断和及时干预，增加了寻求适当治疗的人数。医生和医疗保健专业人员越来越多地开出速效胰岛素，以帮助患者更好地控制餐后血糖，并预防高血糖发作和长期併发症。此外，政府和医疗保健组织正在投资糖尿病管理计划，改善获得基本药物的机会，包括速效胰岛素。意识的提高、医疗设施的改善以及糖尿病治疗负担能力的提高，为速效胰岛素市场的扩张创造了有利的环境。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球速效胰岛素市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 赖脯胰岛素
    • 市场趋势
    • 市场预测
  • 门冬胰岛素
    • 市场趋势
    • 市场预测
  • 谷赖胰岛素
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依迹象

  • 1 型糖尿病
    • 市场趋势
    • 市场预测
  • 2 型糖尿病
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场趋势
    • 市场预测
  • 药局和零售药局
    • 市场趋势
    • 市场预测
  • 网上商店
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adocia
    • Biocon Limited
    • Eli Lilly and Company
    • Gan & Lee Pharmaceuticals Co. Ltd.
    • Geropharm
    • MannKind Corporation
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Sanofi SA
    • Wockhardt Ltd.
Product Code: SR112024A4783

The global rapid acting insulin market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

Rapid Acting Insulin Market Trends/Drivers:

The Increasing Prevalence of Diabetes Among the Masses

The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.

Continual Technological Advancements

Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient's overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.

Increasing Awareness and Healthcare Infrastructure

Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.

Rapid Acting Insulin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

  • Lispro Insulin
  • Aspart Insulin
  • Glulisine Insulin

Lispro insulin dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes lispro insulin, aspart insulin and glulisine insulin. According to the report, lispro insulin represented the largest segment.

Lispro insulin's popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.

Breakup by Indication:

  • Type 1 Diabetes
  • Type 2 Diabetes

Type 2 diabetes hold the largest share in the market

A detailed breakup and analysis of the market based on the indication has also been provided in the report. This includes type 1 diabetes and type 2 diabetes. According to the report, type 2 diabetes accounted for the largest market share.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drug stores and retail pharmacies hold the largest share in the market

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, drug stores and retail pharmacies and online stores. According to the report, drug stores and retail pharmacies accounted for the largest market share.

Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.

Competitive Landscape:

Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Adocia
  • Biocon Limited
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals Co. Ltd.
  • Geropharm
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Wockhardt Ltd.

Recent Developments:

  • In November 2022, Biocon Limited Completes Acquisition of Viatris' Global Biosimilars Business. The acquisition provides Biocon Biologics with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors.
  • In July 2022, Merck & Co. Inc. announces its collaboration with Orion, Global Collaboration for the Development and Commercialization of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer.
  • In May 2022, MannKind Corporation Announces Agreement to Acquire V-Go(R) Insulin Delivery Device from Zealand Pharma. The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Key Questions Answered in This Report:

  • How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
  • What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
  • What are the key regional markets?
  • Which countries represent the most attractive rapid acting insulin market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the rapid acting insulin market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the rapid acting insulin market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the rapid acting insulin market?
  • What is the competitive structure of the global rapid acting insulin market?
  • Who are the key players/companies in the global rapid acting insulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Rapid Acting Insulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Lispro Insulin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Aspart Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Glulisine Insulin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Type 1 Diabetes
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Type 2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adocia
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Biocon Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Geropharm
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 MannKind Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Wockhardt Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials

List of Figures

  • Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
  • Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2023
  • Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2023
  • Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
  • Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
  • Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
  • Table 7: Global: Rapid Acting Insulin Market: Key Players